Table 3 Ongoing trials of septic patients treated with prolonged and intermittent infusion of β-lactam antibiotics
Study | Date of first enrolment | Type | Country | Patients | β-Lactam antibiotics | Primary outcomes | ID of the trial | Sample, N | Phase |
|---|---|---|---|---|---|---|---|---|---|
ANZCTR | 2010/4/14 | RCT | Australia, Hongkong | Severe sepsis | Ticarcillin/clavulanate, Piperacillin/tazobactam, Meropenem | Plasma antibiotic concentration above the MIC for three samples taken on days 3 and 4 | ACTRN12610000238077 | 60 | 2 |
PACTR | 2020/9/21 | RCT | South Africa | Adult and pediatric with Sepsis | Amoxicillin/clavulanate, Piperacillin/tazobactam, Meropenem, Imipenem | Pediatrics: the proportion of patients in the IB group with an expected time above MIC. Adults: clinical cure rates at day 14 | PACTR202009811610400 | 408 | NA |
BLING III | 2018/3/26 | Open-label RCT | Australia, New Zealand, the United Kingdom, Belgium | Sepsis | Piperacillin/tazobactam, Meropenem | Mortality at day 90 | NCT03213990 | 7203 | 3 |
BICCS | 2023/8/1 | Open-label RCT | France | Sepsis or septic shock | β-Lactam antibiotics | Mortality at day 30 | NCT05681442 | 600 | 4 |
PROBES | 2021/9/20 | Open-label RCT | China | Early Septic Patients | β-Lactam antibiotics | All-cause mortality in ICU; 28-day all-cause mortality | NCT05024565 | 2600 | NA |
PAACS | 2018/7/16 | Open-label; Non-RCT | France | Early Septic Patients | Piperacillin/tazobactam, Cefepime, Meropenem | Proportion of patients achieving the PK/PD target; all-cause mortality | NCT02820987 | 129 | 3 |